Biosimilars Pipeline (Oncology Focus)

About Aurobindo Pharma

Founded in 1986, Aurobindo Pharma has grown from an API manufacturer into a global generics powerhouse with a mission to make medicines affordable and accessible worldwide. Its core strategy leverages deep vertical integration, significant manufacturing scale (29 facilities producing 50+ billion formulation units annually), and a strategic pivot towards high-value complex generics, injectables, and biosimilars. Key achievements include a portfolio of over 830 ANDA filings in the US with 600+ approvals, leadership in antiretroviral therapies, and the recent inauguration of a flagship Penicillin-G facility, underscoring its commitment to backward integration and supply chain resilience.

Therapeutic Areas

Other Oncology Drugs